Trial Profile

A Phase 2 Multicenter Study of Autologous Tumor Infiltrating Lymphocytes (TIL or LN-145) in Patients With Metastatic Non-Small-Cell Lung Cancer

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 11 Nov 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Lifileucel (Primary) ; Aldesleukin; Cyclophosphamide; Fludarabine
Indications Adenocarcinoma; Carcinoma; Non-small cell lung cancer; Squamous cell cancer
Focus Registrational; Therapeutic Use
Sponsors Iovance Biotherapeutics

29 Oct 2026 According to an Iovance Biotherapeutics media release, positive results from the trial will be presented via live webcast.
29 Oct 2026 According to an Iovance Biotherapeutics media release, The broader IOV-LUN-202 Cohorts 1 and 2 are completing enrollment, with approximately 80 non-squamous NSCLC patients expected in the final dataset, and an sBLA for lifileucel in non-squamous mNSCLC is planned for 2027.
29 Oct 2026 Results from Cohorts 1 and 2 of the trial were presented in an Iovance Biotherapeutics media release.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com